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Abstract  1 
Background 2 
Loss of skeletal muscle mass and muscle weakness are common in a variety of 3 
clinical conditions with both wasting and weakness associated with an impairment of 4 
physical function. ß-hydroxy-ß-methylbutyrate (HMB) is a nutrition supplement that 5 
has been shown to favourably influence muscle protein turnover and thus has a 6 
potential role in ameliorating skeletal muscle wasting and weakness.  7 
Objective 8 
To investigate the efficacy of HMB alone, or supplements containing HMB, on 9 
skeletal muscle mass and physical function in a variety of clinical conditions 10 
characterized by loss in skeletal muscle mass and weakness. 11 
Design 12 
A systematic review and meta-analysis of randomized controlled trials reporting 13 
outcomes of muscle mass, strength and physical function was performed. Two 14 
reviewers independently performed screening, data extraction, and risk of bias 15 
assessment. Outcome data were synthesized through meta-analysis using a 16 
random-effects model and data presented as standardized mean differences 17 
(SMDs). 18 
Results 19 
Fifteen RCTs were included, involving 2137 patients. Meta-analysis revealed some 20 
evidence to support the effect of HMB alone, or supplements containing HMB, on 21 
increasing skeletal muscle mass (SMD = 0.25; 95% CI -0.00, 0.50; Z = 1.93; P = 22 




0.31; 95% CI 0.12, 0.50; Z = 3.25; P = 0.001; I2 =0%). Effect sizes were small. No 24 
effect on bodyweight (SMD = 0.16; 95% CI = -0.08, 0.41; Z = 1.34; P = 0.18; I2 = 25 
67%) or any other outcome was found. No study was considered to have low risk of 26 
bias in all categories. 27 
Conclusion 28 
HMB, and supplements containing HMB, increased muscle mass and strength in a 29 
variety of clinical conditions, although the effect size was small. Given the bias 30 
associated with many of the included studies, further high quality studies should be 31 
undertaken to enable interpretation and translation into clinical practice. 32 
 33 
KEYWORDS: ß-hydroxy-ß-methylbutyrate, HMB, muscle, strength, nutrition, 34 
malnutrition, cancer cachexia, critical illness, sarcopenia 35 
 36 
 37 





Skeletal muscle wasting and weakness commonly occur with immobilisation and 40 
disuse (1), malnutrition (2), age-related sarcopenia (3), cancer cachexia (4) and 41 
during early critical illness (5).  Furthermore, reduced muscle mass is associated 42 
with impaired physical function (6) and frailty (3), which drive morbidity (2, 7) and 43 
mortality (8-10). Interventions that can ameliorate, or even prevent, loss of muscle 44 
mass and improve physical function are a key clinical priority. 45 
Depending on the technique used, skeletal muscle can be measured or estimated as 46 
either fat-free mass (FFM) or lean mass, although accuracy is variable (11). For 47 
example, bioelectrical impedance analysis (BIA) estimates FFM (sum of lean body 48 
mass and the bone mineral compartments) whereas DXA measures lean mass 49 
(body water, total body protein, carbohydrates, non-fat lipids, and soft tissue mineral) 50 
(11). Given the variety of techniques used to measure these body components, and 51 
that skeletal muscle is an important component of both fat free and lean mass, the 52 
term ‘muscle mass’ is used throughout this systematic review. 53 
Muscle mass is maintained by a balance between muscle protein synthesis and 54 
muscle protein catabolism. Both resistance exercise and amino acid loading can 55 
enhance protein balance (12), however, resistance exercise is challenging, in 56 
particular during acute illness. This is compounded by insufficient protein intake in 57 
acute and chronic clinical patient populations (13-16) with anabolic resistance 58 
present in older patients (17, 18). For this reason, investigating novel interventions 59 
such as amino acids and their metabolites, which are not purely reliant on factors 60 




-hydroxy--methylbutyrate (HMB) is a metabolite of the amino acid, leucine, and its 62 
effects on skeletal muscle mass and strength has been investigated in athletes (19). 63 
HMB has several proposed mechanisms of action including stimulation of the 64 
mammalian target of rapamycin (mTOR) which leads to increased protein synthesis 65 
(20, 21) and attenuation of the proteasome pathways that lead to muscle protein 66 
catabolism (22, 23). Positive effects of HMB supplementation on maintenance of 67 
muscle mass in healthy older people undertaking bed rest, even in the absence of an 68 
exercise regimen, indicates this may be an efficacious nutrition intervention for 69 
immobile patients, such as during early critical illness (24). The effects of HMB 70 
supplementation have been studied in a variety of clinical conditions where muscle 71 
wasting is present, including critical illness (25), human immunodeficiency virus 72 
(HIV) (26) and cancer cachexia (27) with varying results. 73 
The aim of the current study was to undertake a systematic review and meta-74 
analysis to investigate the effects of HMB alone, and supplements containing HMB, 75 
on skeletal muscle mass and physical function in a variety of clinical conditions 76 
characterized by loss of muscle mass and skeletal muscle weakness. 77 
MATERIALS & METHODS 78 
This systematic review and meta-analysis was performed following guidelines from 79 
the Cochrane Handbook for Systematic Reviews of Interventions (28) and reported 80 
according to the Preferred Reporting Items for Systematic Reviews and Meta-81 
Analysis (PRISMA) guidelines (29). The protocol was pre-registered on PROSPERO 82 
(CRD42017058517). 83 
 84 




A literature search for randomized controlled trials investigating the effect of HMB, 86 
and supplements containing HMB on muscle mass, strength or physical function in 87 
adult patients was conducted using electronic searching of four literature databases, 88 
two clinical trials databases, hand-searching of abstracts from three conference 89 
proceedings, back-searching of reference lists and discussions with key opinion 90 
leaders. One investigator (DEB) performed a database search (last search date 25 91 
September 2018) using MEDLINE, Web of Science, EMBASE and CINAHL using a 92 
pre-determined search strategy (Supplemental Methods). Limits were applied to 93 
the electronic search, restricting studies to those including adults and humans, and 94 
published in the English language only. No date range restrictions were applied. The 95 
international trial databases Clinical Trials (www.clinicaltrials.gov) and ISRCTN 96 
(www.ISRCTN.com), were also searched for completed, unpublished studies. 97 
Abstracts of the following conference proceedings were hand-searched to identify 98 
any potentially relevant studies: American Society for Parenteral and Enteral 99 
Nutrition, European Society of Clinical Nutrition and Metabolism, and the Society of 100 
Sarcopenia, Cachexia and Wasting Disorders. Reference lists of relevant studies 101 
and previous systematic reviews were manually reviewed for additional studies not 102 
identified in the electronic search. 103 
Study selection  104 
After removing duplicates and non-relevant material, titles and abstracts identified 105 
from the search were screened independently by two investigators (DEB, AL). 106 
Potentially eligible studies had their full texts screened for eligibility by the same two 107 
investigators (DEB, AL). Inclusion and exclusion criteria are shown in Table 1. 108 
Data extraction was performed independently by two investigators (DEB, AL) using a 109 




corrected where appropriate. The data extracted included author details, year of 111 
publication, participant characteristics, details of intervention and control and results 112 
relating to the aim of the systematic review. Authors of the included studies were 113 
contacted to obtain missing data where required. 114 
Assessment of risk of bias 115 
Risk of bias was assessed independently by two investigators (DEB, AL) according 116 
to the Cochrane Collaboration Risk of Bias Tool (28). Studies were assessed at both 117 
the individual and study level and included the methods used to generate 118 
randomization, conceal allocation, blind participants and personnel along with 119 
assessing incomplete outcome data, selective reporting and other sources of bias.  120 
Where disagreements between the two researchers (DEB, AL) on study eligibility, 121 
data extraction and risk of bias assessment were not resolved by consensus, a third 122 
investigator was available to arbitrate (LW). 123 
Data synthesis and statistical analysis 124 
The primary outcome of interest in this systematic review was the change in skeletal 125 
muscle mass. Secondary outcomes included the effect on body composition, 126 
strength, physical function and surrogate markers of muscle wasting.  127 
Meta-analyses were performed on the extracted data, where appropriate, using a 128 
random effects model in Review Manager 5.3 (RevMan5, Copenhagen, Denmark). 129 
Where studies included multiple time points, data from the end of the intervention 130 
was used in the overall meta-analysis. However, sub-analyses were also performed 131 
on outcome data measured in four-week epochs (0-4 weeks, 4-8 weeks, 8-12 132 
weeks, >12 weeks) in order to determine any effects of the duration of the 133 




mass or strength (e.g. both BIA and air displacement plethysmography or handgrip 135 
and leg extensor strength), data from the most frequently used method across the 136 
studies was used in the overall meta-analyses. However, sub-analyses were also 137 
performed on each method of measuring the outcome where adequate (≥3) studies 138 
were available.  139 
Given the varying methods used to measure muscle mass and strength, standard 140 
mean difference (SMD) with 95% confidence intervals (CI) were used to express 141 
effect size estimates. SMD values of 0.2, 0.5 and 0.8 were defined as small, 142 
moderate and large effect sizes respectively (30). One study did not present results 143 
for the overall group and therefore the results of the two subgroups were entered as 144 
independent groups in the meta-analyses (31).  145 
As the reporting of outcome data varied across studies (absolute values at end of 146 
intervention, change scores), change scores were calculated from the available data 147 
and standard deviations imputed according to the Cochrane Handbook for 148 
Systematic Reviews of Interventions (28). Where two standard deviations were 149 
calculated, we imputed the largest to reduce the bias associated with this method. 150 
 Where change data were presented, but without mean and standard deviation or 151 
standard error, SMD was calculated from the reported p value. Studies reporting only 152 
median and interquartile range were converted to mean and standard deviations 153 
using a referenced formula (32). If more than half of studies included in a meta-154 
analysis required imputation of standard deviations, rather than imputing change 155 
scores, the value at the end of the intervention period was used for that outcome. 156 
The meta-analysis for muscle strength was the only outcome where this was done. 157 




effect of HMB presentation (e.g. alone, in ONS or combined with amino acids) on 159 
overall outcome.  160 
Heterogeneity of results between studies was determined by I2, with values of 25-161 
49.9% considered low, 50-74.9% considered moderate and 75-100% considered 162 
high heterogeneity. Test for overall effect (Z score) was regarded significant at P  163 
0.05. Effect sizes were also relied upon as these are of greater clinical relevance and 164 
recommended by both the American Statistical Association (33) and the Cochrane 165 
Handbook for Systematic Reviews of Interventions (28). Funnel plots were 166 
generated to assess for evidence of asymmetry and possible publication bias or 167 
effects due to the small size of some studies (34).  168 
RESULTS 169 
Study Selection 170 
A total of 1426 results were generated from the search strategy (Figure 1). None 171 
were obtained from discussions with experts in the field or back-searching reference 172 
lists and hand-searching conference abstracts. After duplicates were removed, 840 173 
records were available for title and abstract screening. Of these, 21 records were 174 
retrieved for full-text screening with 15 RCTs being eligible for inclusion.  175 
 176 
 177 
Study characteristics 178 
The 15 eligible RCTs involved a total of 2137 adults (25-27, 31, 35-45). Authors of 179 
seven studies were contacted to provide additional data, of whom only one provided 180 
the requested data. All studies included patients who commonly experience muscle 181 




receiving tube feeding (n=1) (36), hospitalised older people with malnutrition / 183 
sarcopenia (n=2) (31, 43), hospitalised older people undergoing orthopaedic 184 
intervention (n=3) (38, 42, 44), critically ill (n=2) (25, 35), cancer cachexia (n=2) (27, 185 
41), HIV (n=1) (26), maintenance haemodialysis (n=1) (39), rheumatoid cachexia 186 
(n=1) (40), gastric bypass (n=1) (45) and bronchiectasis (n=1) (37). Study 187 
characteristics and intervention data are reported in Table 2. 188 
Three of the studies used HMB as a single supplement (35, 36, 39), seven used 189 
HMB in combination with arginine and glutamine (HMB/ARG/GLN) (25-27, 38, 40, 190 
41, 45) and five used a high protein oral supplement containing HMB and other 191 
nutrients (31, 37, 42-44) (Table 2). All but one study (35) provided a dose of 3 g/d 192 
HMB. There was considerable variability in the duration of the intervention, ranging 193 
from seven days to six months (Table 2).  194 
Risk of bias 195 
No study was considered low risk of bias in all categories. Blinding of participants 196 
and personnel was uncommon, whilst selection (random sequence generation) and 197 
attrition bias had the lowest overall risk of bias (Figure 2). 198 
 199 
 200 
Skeletal muscle mass  201 
Ten of the 15 included studies reported measures of skeletal muscle mass (either 202 
FFM or lean mass) (26, 27, 31, 37-41, 44, 45) using DXA (31, 37, 39, 40, 45), air 203 
displacement plethysmography (Bod Pod) (26, 27), BIA (27, 37, 41, 44) or computed 204 
tomography (CT) (38) with measurement periods ranging from 4 weeks to 6 months 205 




Meta-analysis was possible for 9 of these 10 studies (26, 27, 31, 37-40, 44, 45). 207 
Change scores were calculated from the available data and standard deviations 208 
imputed for four studies (37-39, 44). Median and interquartile range were converted 209 
to mean and standard deviation in one study (31). Some evidence was found to 210 
support supplementation with HMB alone, or supplements containing HMB, on 211 
increasing skeletal muscle mass compared with control, but the effect size was small 212 
(SMD = 0.25; 95% CI -0.00, 0.50; Z = 1.93; P = 0.05) (Figure 3). Moderate 213 
heterogeneity was present between studies (I2 = 58%, p = 0.01). 214 
Sub-group analyses according to the type of supplementation (HMB alone, 215 
combined with arginine and glutamine or within an ONS) revealed some evidence to 216 
support an increase in muscle mass when HMB/ARG/GLN was used, with a 217 
moderate effect size (SMD = 0.49, 95% CI -0.01, 0.99, Z = 1.93; P = 0.05; I2 67%, 218 
p=0.02. (Figure 3). 219 
Four studies included muscle mass measurements at multiple time points (27, 31, 220 
37, 45). Therefore, sub-group analysis was performed according to duration of the 221 
intervention. No evidence was found to support improvements in muscle mass when 222 
the intervention was provided less than 4 weeks (27, 44, 45) (SMD = 0.34, 95% CI -223 
0.21, 0.90, Z = 1.22; P = 0.22; I2 = 69%, p=0.04), 4-8 weeks (26, 38, 45) (SMD = 224 
0.60, 95% CI -0.06, 1.25; Z = 1.79, P= 0.07; I2 =59%, p=0.09), 8-12 weeks (31, 37, 225 
40) (SMD = 0.16, 95% CI -0.28, 0.59, Z = 0.71, P = 0.48, I2 = 76%, p=0.005) and 226 
greater than 12 weeks (27, 31, 37, 39) (SMD = 0.08, 95% CI = -0.12, 0.28, Z = 0.79, 227 
P = 0.43; I2 = 0%, p=0.62). 228 
The study by Berk et al (41) was excluded from meta-analysis as only percent 229 




from the data reported. This study showed no difference in muscle mass in cancer 231 
cachexia following 8-weeks supplementation with HMB/ARG/GLN.  232 
Body weight and composition 233 
Thirteen studies measured body weight (26, 27, 31, 35-38, 40-45), six studies 234 
reported fat mass (27, 31, 37, 39, 40, 44), three studies reported mid-arm muscle 235 
circumference (36, 37, 42) three reported triceps skin fold (TSF) (26, 36, 41) and two 236 
reported thorax, calf, waist and hip circumference (36, 42).  237 
Meta-analysis for change in bodyweight could be performed for 12 of the 13 studies 238 
(26, 27, 31, 35-38, 40, 42-45). One was excluded as only percent change in 239 
bodyweight was reported (41). Four of the included studies had change scores 240 
calculated from the available data and standard deviations imputed (37-39, 44). 241 
Median and interquartile range were converted to mean and standard deviation in 242 
one study (31). There was no evidence to support the effect of HMB, or supplements 243 
containing HMB on change in bodyweight in the overall meta-analysis (SMD = 0.16; 244 
95% CI = -0.08, 0.41; Z = 1.34; P = 0.18) or in sub-group analysis according to 245 
supplement type (Figure 4). Heterogeneity was moderate (I2 = 67%, p=0.0003).  246 
All six studies reporting fat mass were included for meta-analysis (27, 31, 37, 39, 40, 247 
44). Four of the included studies had change scores calculated from the available 248 
data and standard deviations imputed (37-39, 44) and median and interquartile 249 
range were converted to mean and standard deviation in one study (31). Overall, 250 
there was no evidence to support a change in fat mass between patients receiving 251 
HMB and controls (SMD = 0.03; 95% CI -0.27, 0.34; Z = 0.21; P=0.83; I2 = 58%; 252 




Studies reporting other measures of body composition were unsuitable for meta-254 
analysis. No difference in TSF was reported in three studies (36, 41, 42). Measures 255 
of arm or body area circumference were reported in three studies (36, 37, 42), 256 
however only Hsieh et al (36) reported a greater increase in waist circumference 257 
after 14 days of HMB alone vs. control (0.97 ±4.46% vs -0.89 ±4.45%, p=0.026), 258 
which continued to day 28 of supplementation (2.24 ±4.64% vs -3.42 ±4.45%, 259 
p<0.05) with additional gains in calf circumference at this time point (2.57 ±5.02% vs 260 
-3.63±4.24%, p<0.05). Baseline difference in BMI were controlled for in this study.  261 
Muscle strength 262 
Measures of strength were reported in seven studies (31, 37-40, 42, 44), specifically 263 
isokinetic knee extensor and elbow flexor strength and handgrip strength. Absolute 264 
strength at the end of the intervention period was used for this meta-analysis. Six 265 
studies (37-40, 42, 44) were included in the meta-analysis revealing strong evidence 266 
that HMB or supplements containing HMB improved muscle strength compared with 267 
controls, but with a small to moderate effect size (SMD = 0.31; 95% CI 0.12, 0.50; Z 268 
= 3.25; P = 0.001; I2 =0%) (Figure 5). Sub-group analysis according to supplement 269 
type demonstrated strong evidence to support the use of HMB alone (SMD = 0.26, 270 
95% CI -0.00, 0.53, Z = 1.95, P = 0.05) and ONS containing HMB (SMD = 0.37; 95% 271 
CI 0.06, 0.68; Z=2.31; P=0.02; I2 = 0%) on improving muscle strength (Figure 6), 272 
although there was only one study providing HMB alone. Effect sizes were small to 273 
moderate.  274 
Three studies measured handgrip strength only (37, 42, 44), two studies measured 275 
leg strength only (38, 39), one study measured both handgrip and leg strength (31) 276 
and one study measured handgrip, leg and elbow strength (40). There was strong 277 




0.66; Z = 2.63, P = 0.008; I2 = 0%, p=0.75) (Supplemental Figure 1) and leg 279 
extensor strength (SMD = 0.28, 95% CI 0.08, 0.48, Z = 2.73, P= 0.006; I2 = 0%, 280 
p=0.85) (Supplemental Figure 2) with the intervention. However, effect sizes were 281 
small to moderate. 282 
The study by Cramer et al (31) was excluded from this meta-analysis as only data on 283 
change in handgrip and leg strength are provided. Leg strength was measured at 12 284 
and 24 weeks. There were no differences found between treatment groups for leg 285 
strength in the overall study population, but participants classified as having 286 
sarcopenia and normal grip strength displayed significantly greater increases in leg 287 
strength in the intervention compared with control group (p=0.032).  288 
Physical Function 289 
Four studies reported measures of functional ability (31, 39, 40, 44), including gait 290 
speed (31, 39, 44), sit-to-stand (39, 40), shuttle walk (39) and the 8 foot up-and-go 291 
test (39). Meta-analysis could not be performed due to the nature of data reporting. 292 
None of the four studies reported between-group differences in any outcome of 293 
physical function, however two studies reported no significant changes in physical 294 
function in the HMB group (39, 44) and two studies reported within-group 295 
improvements in physical function over time in the HMB group (31, 40).  296 
Surrogate markers of muscle wasting 297 
Six studies reported surrogate markers of muscle wasting including blood urea 298 
nitrogen (BUN) (26, 27, 35, 36, 39), urinary urea nitrogen (UUN) (36), nitrogen 299 
balance and 3-methylhistidine (3-MH) excretion (25). Meta-analysis was not possible 300 
due to the reporting of data or an insufficient number of studies to include in the 301 




Although BUN and UUN were reported in several studies, only two specifically 303 
investigated these as a surrogate marker of muscle wasting (35, 36) whilst the others 304 
measured these to investigate the safety of taking either HMB or a mixed amino acid 305 
supplement containing HMB (HMB/ARG/GLN) (26, 27, 39). Results from the studies 306 
were inconsistent. Only one study found a significant decrease in BUN in the 307 
intervention group at day 14, but not day 28 of the study period (36). In contrast, May 308 
et al (27) report a significant increase in BUN in the group receiving HMB/ARG/GLN 309 
compared with a decrease in the control which was significantly different between 310 
the two groups (P<0.05). Clark et al (26) also report an increase in BUN in the 311 
HMB/ARG/GLN group, but overall results were not displayed. Lastly, Fitschen et al 312 
(39), report that BUN differences between the groups were not significant.  313 
In the one study reporting UUN as a surrogate measure of muscle wasting, the 314 
change in 24-hour UUN excretion was significantly lower in the group receiving HMB 315 
compared with control participants at both 14 days (-12.5% vs 29.7%, p=0.02) and 316 
28 days (-30.7% vs 15.7%, p<0.001) (36). Kuhls et al (25) reported no difference in 317 
UUN excretion between the three groups (HMB alone, HMB/ARG/GLN or placebo), 318 
but nitrogen balance was significantly improved following HMB alone compared with 319 
the HMB/ARG/GLN from day 1 to day 7 and from day 8 to day 14 (p<0.05). The 320 
control group were also in greater negative nitrogen balance compared to the HMB 321 
alone, but this was not significant (p<0.08). Muscle proteolysis as measured by 3-MH 322 
was not different between the three groups.  323 
Other clinical outcomes 324 
Other clinical outcomes included inflammation (35) or infections (SIRS score) (25), 325 
degree of sepsis (25), mortality (43), hospital and ICU length of stay (25, 43) and 326 




Kuhls et al (25), found a decreased incidence of patients with SIRS score 3 or 4 on 328 
days 3 and 7 in the HMB group, but no difference in other clinical outcomes. The use 329 
of an ONS containing HMB compared to placebo reduced 90-day mortality in one 330 
study (4.8% vs. 9.7%, p=0.018), but this was a secondary outcome (43). No other 331 
differences were reported as significant for the remaining clinical outcomes. 332 
Adverse events 333 
Five studies reported absolute numbers or percentages of adverse events (31, 36, 334 
40, 41, 43). Marcora et al (40), reported significantly lower proportion of participants 335 
with gastrointestinal discomfort in those receiving HMB/ARG/GLN compared with 336 
placebo (28% vs. 67% p = 0.02). Hsieh et al (36), reported that some patients 337 
dropped out due to the development of scabs, but numbers and groups were 338 
unclear.  The other three studies reported similar numbers of adverse events 339 
between groups.  340 
Publication bias 341 
Visual inspection of the funnel plots for all outcomes did not reveal substantial 342 
asymmetry and therefore publication bias (Supplemental Figures 3-5). Statistical 343 
tests to explore funnel plot asymmetry were not undertaken due to the use of SMD in 344 
the meta-analysis as per the recommendations of the Cochrane Handbook for 345 
Systematic Reviews of Interventions (28).  346 
 347 
DISCUSSION 348 
This systematic review and meta-analysis aimed to investigate the effects of HMB, 349 
and supplements containing HMB, on skeletal muscle mass and physical function in 350 




muscle weakness, including ageing and critical illness. We found some evidence to 352 
support a positive effect of HMB on the change in muscle mass and strong evidence 353 
to support an increase in absolute muscle strength. However, the effect size was 354 
small in both instances. Sub-group analysis indicated that participants receiving 355 
HMB and supplements containing HMB were significantly stronger compared with 356 
the control group, but with only a small to moderate effect size.  These findings may 357 
have important clinical implications given the well-documented detrimental effects of 358 
low muscle mass and skeletal muscle wasting in a number of clinical conditions (6-359 
10).  Of major clinical relevance, is that HMB alone, and supplements containing 360 
HMB, have a strong safety profile without increased incidence of adverse events 361 
compared to placebo or standard care groups used across this range of clinical 362 
conditions.  363 
To our knowledge, this is the first meta-analysis investigating the effect of HMB on 364 
strength in a variety of clinical conditions. As it is common for studies to use multiple 365 
measurements for each outcome, we also performed separate meta-analysis for the 366 
outcomes of handgrip strength and leg extensor strength and observed that 367 
evidence in support of this remained strong providing further support for the use of 368 
HMB and supplements containing HMB.  369 
Of interest, none of the studies included in the meta-analysis for strength reported a 370 
between group difference in absolute muscle mass following the intervention. This is 371 
perhaps unsurprising given the complex relationship between nutritional status and 372 
muscle mass, muscle quality, muscle strength and physical function that is non-373 
linear. Indeed, an improvement in muscle quantity may not translate to a proportional 374 
improvement in volitional, or non-volitional, force production (46), and in turn a 375 




requires coordination of cognitive and executive function. Furthermore, establishing 377 
a true baseline of physical functional status is challenging in the absence of robust 378 
markers to determine pre-morbid ability. Careful consideration should be given to 379 
selection of these outcomes in such trials (47).  380 
Despite including a potentially heterogeneous group of adult patients, the results of 381 
the current study provide some evidence to support the beneficial effect of HMB on 382 
muscle mass and strong evidence to support the effect on strength. This is in line 383 
with previous systematic reviews that have reported the effect of HMB in older 384 
people (48) and athletes (19). By only including studies in adults with a clinical 385 
condition associated with skeletal muscle wasting, the current systematic review and 386 
meta-analysis is unique and of major clinical importance as it highlights the potential 387 
of using HMB, and supplements containing HMB, in the management of a variety of 388 
clinical conditions characterised by skeletal muscle wasting and weakness. 389 
Interestingly, the increase in muscle mass reported in this current study was 390 
observed without changes in either body weight or FFM, although this may be more 391 
reflective of methodological differences in the included studies rather than any 392 
mechanistic effect of HMB itself and should be interpreted with caution. 393 
Many conditions, such as critical illness and cancer cachexia, result in reduced 394 
muscle mass (4, 5), strength and physical function (2, 3, 6). Whilst the shared 395 
common pathway is an imbalance between muscle protein synthesis and muscle 396 
protein breakdown, the specific intra-cellular proximal signalling pathways leading to 397 
this differ between conditions (5, 49). Older patients also display anabolic resistance 398 
whereby muscle protein synthesis is resistant to stimuli such as resistance training 399 
and amino acid loading (17, 18), a serious clinical consideration with an increasing 400 




hallmark of critical illness (1, 51) and other acute clinical conditions, could further 402 
contribute to skeletal muscle wasting. Interventions that target muscle protein 403 
turnover, in terms of reducing muscle protein breakdown and enhancing muscle 404 
protein synthesis as well as reducing inflammation (52), such as HMB, are of 405 
increasing clinical interest.  406 
Interventions varied in the studies in this systematic review and included HMB alone, 407 
HMB in combination with the amino acids arginine and glutamine and HMB in ONS 408 
with high protein and vitamin D. However, there was relative consistency in the 409 
doses used across studies, being 3 g/d for all but one study, which used 4 g/d (36), 410 
and any future studies should consider a minimum dose of 3g/d. Regarding the 411 
combined preparations of HMB that have been used (HMB/ARG/GLN, HMB in 412 
ONS), although such an approach may be potentially beneficial, these distract from 413 
our understanding of the mechanism of action of HMB alone on skeletal muscle 414 
anabolism and catabolism as protein and vitamin D impact muscle mass gain and 415 
muscle strength but through differing mechanisms (12, 20, 21, 53).  416 
Strengths and limitations  417 
This systematic review and meta-analysis has several strengths related to the robust 418 
methodological approach. The protocol was pre-registered on PROSPERO and all 419 
eligibility screening, data extraction and risk of bias assessment was undertaken 420 
independently in duplicate, with a third person available for arbitration if required, 421 
thus limiting the potential for error and bias.  422 
The limitations of this systematic review relate to the quality of the design and 423 
reporting of the included studies. First, although we contacted seven authors to 424 




combined with inconsistent reporting of data across studies, required some standard 426 
deviations to be imputed (28). No study was considered at low risk of bias across all 427 
domains. Most prominent was the lack of blinding and compliance with the 428 
intervention was a significant issue in several of the studies.  429 
The studies included utilised varying measures of body composition analysis 430 
including dual energy X-ray absorptiometry, air displacement plethysmography (Bod 431 
Pod), CT and BIA, with some studies using more than one method. It is possible that 432 
HMB may influence different compartments of FFM and lean mass differently and 433 
therefore these techniques may provide different results depending upon the 434 
compartments measured and the choice of measurement techniques for strength 435 
and physical function may influence results (e.g. handgrip vs. leg-extensor strength). 436 
Thus, techniques to measure both muscle mass and strength should be carefully 437 
considered in future trials of HMB. 438 
Although we also included surrogate markers of muscle wasting as an outcome 439 
measure, these results are more difficult to interpret. The rationale for BUN and UUN 440 
as surrogate markers for muscle wasting is controversial and measuring nitrogen 441 
balance in the critically ill population has several limitations (54). Future studies 442 
should investigate muscle protein turnover using stable isotopes to ensure the 443 
reporting of more precise indications of the effect of HMB on muscle wasting.   444 
Conclusion 445 
Investigating interventions that reduce skeletal muscle wasting and maintain or 446 
improve muscle mass are a clinical priority. This systematic review and meta-447 
analysis of RCTs found that HMB alone, and supplements containing HMB, improve 448 




size was small to moderate. Furthermore, sub-group analysis revealed strong 450 
evidence to support the use of HMB to increase muscle strength. However, given the 451 
bias associated with many of the included studies, further, high quality RCTs should 452 
be undertaken with greater methodological rigor. 453 
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Table 1 - Inclusion and exclusion criteria used to evaluate studies for the systematic 
review 










Adult (≥ 18 years) with a primary 
clinical diagnosis (eg. chronic 
obstructive pulmonary disease, 
cancer, malnutrition)  
In- or outpatient setting 
 




Minimum 1.5 g/d β-hydroxy-β-
methylbutyrate either alone or in 
combination with other nutrients 












Muscle mass (measured by any 
means), body composition 
(measured by any means), 
strength, physical function  
 
Specified outcome 
measures not investigated 










Table 2 - Study characteristics of included trials. 
Study Patient 
population 




outcome relevant to 
review 
Other outcomes 
Hsieh (35)  Mechanically 
ventilated 
COPD 
I: 78.8 (9.7) 
C: 78.3 (7.4) 
I: 21.1 (3.72) 
C: 18.69 
(3.33) 
HMB 3 g (2 x 1.5.g 
doses / d) 
 
 







Hsieh (36) Tube fed older 
people 
I: 72.5 (11.8) 
C: 70.8 (9.8) 
I: 19.2 (4) 
C: 21.6 (3.1) 



















I: 57 (8) 
C: 53 (13) 
I: 31.9 (7) 
C: 30.8 (6.4) 






6 months Body composition 
(DXA, body weight) 
Muscle strength (knee 












NR HMB 3 g 
L-arginine 14 g 
L-glutamine 14 g  
 
(2 x HMB 1.5 g, L-
arginine 7 g, L-
glutamine 7 g doses / 
d) 
 
Maltodextrin 8 weeks Body composition 
(body weight, forearm, 
upper arm and thigh 
circumference, TSF, 
Bod Pod, CT thigh) 
Blood chemistry (liver 
function tests, blood 
lipids, hematologic 










I: 66 (2.3)3,6 
C:66 (2.1)3.6 
NR HMB 3 g 
L-arginine 14 g 
L-glutamine 14 g  
 
(2 x HMB 1.5 g, L-
arginine 7 g, L-








11 g, L-glutamic 
acid 1.75 g, L-
glycine 6.10 g, 
L-serine 4.22 g) 
 
24 weeks Body composition 
(body weight, BIA, 
Bod Pod) 
 






I: 54 (10) 
C: 57 (8) 
I: 25.2 (4.1) 
C: 27.2 (4.8) 
HMB 3 g 
L-arginine 14 g 
L-glutamine 14 g  
 
(2 x HMB 1.5 g, L-
arginine 7 g, L-







11 g, L-glutamic 
acid 1.75 g, L-
glycine 6.10 g, 
L-serine 4.22 g) 
 









Disease activity index 
Kuhls (25) Mechanically 
ventilated 
trauma 
I: 36 (3.2)6;  
41 (3.2)6 
C: 37 (3.3)6 
NR HMB 3 g 
L-arginine 14 g 
L-glutamine 14 g  
 
(2 x HMB 1.5 g, L-
arginine 7 g, L-





3 g HMB (2 x 1.5 g 





acids (30.6 g of 
hydrolyzed 
gelatin, 7.8 g L-
alanine, 4.2 g L-
glycine, 3.0 g L-
serine, and 1.2 
g L-glutamic 
acid) 













NR HMB 3 g 
L-arginine 14 g 
L-glutamine 14 g  
 
(2 x HMB 1.5 g, L-




acids (30.52 g 
gelatin, L-
alanine 7.72 g, 
8 weeks Body composition 
(body weight, BIA, 
upper arm, forearm, 
chest, hip and thigh 
circumference, 7 site 
Fatigue (Schwartz 
fatigue score) 
Quality of life (Spritzer 








1.23 g, L-glycine 









I: 47.9 (9.6) 
C: 46 (7.5) 
I: 42.9 (4.1) 
C: 43.6 (4.2) 
HMB 3 g 
L-arginine 14 g 
L-glutamine 14 g  
 
(2 x HMB 1.5 g, L-
arginine 7 g, L-
glutamine 7 g doses / 
d) 
 
Usual care 8 weeks Body composition 
(body weight, DXA) 





Bronchiectasis I: 58.4 (12.9) 
C: 53.7 
(13.1) 
I: 25.9 (3.4) 
C: 27.3 (5.8) 
HMB 3 g in  
ONS with 660 kcal, 36 
g protein, 2000 IU 
Vitamin D  
 
(ONS with 1.5 g HMB, 
330 kcal, 18 g protein, 
1000 IU Vitamin D 
twice daily) 
 
Usual care 24 weeks Body composition 
























HMB 3 g in  
ONS with 660 kcal, 36 
g protein, 2000 IU 
Vitamin D  
 
(ONS with 1.5 g HMB, 
330 kcal, 18 g protein, 
1000 IU Vitamin D 
twice daily) 
Usual care  
 
30 days Body composition 














I: 77.7 (8.2) 
C:78.1 (8.6) 
I: 24.3 (5.2) 
C: 23.9 (5) 
HMB 3 g in  
ONS with 660 kcal, 36 
g protein, 2000 IU 




kcal, 12 g CHO, 
10mg Vitamin C 
90 days Post-discharge 
incidence of death or 
non-elective 
readmission 
Length of stay 
SGA class 






(ONS with 1.5 g HMB, 
330 kcal, 18 g protein, 

















I: 25 (23,29)5 
C: 26 
(24,29)5 
HMB 3 g in  
ONS with 660 kcal, 36 
g protein, 2000 IU 
Vitamin D  
 
(ONS with 1.5 g HMB, 
330 kcal, 18 g protein, 




330 kcal, 14 g 
pro, 147 IU 
Vitamin D3 
 
24 weeks Body composition 
(body weight, DXA) 
Strength (grip 
strength, leg strength) 









I: 71.1 (NR) 
C: 69.8 (NR) 
NR HMB 3 g 
L-arginine 14 g 
L-glutamine 14 g  
 
(2 x HMB 1.5 g, L-
arginine 7 g, L-





kcal and 140 mg 
pro 
5 days before 















I: 85.7 (6.5) 
C: 84.7 (6.3) 
I: 24.9 (4.4) 
C: 26 (5.4) 
HMB 3 g in  
ONS with 660 kcal, 36 
g protein, 2000 IU 
Vitamin D  
 
(ONS with 1.5 g HMB, 
330 kcal, 18 g protein, 
1000 IU Vitamin D 
twice daily) 





(body weight, BIA) 
Strength (hand grip 
dynamometry) 
Physical function (gait 
speed) 
 
Plasma Vitamin D 
 
130.6 g of hydrolyzed gelatin, 7.8 g L-alanine, 4.2 g L-glycine, 3.0 g L-serine, and 1.2 g L-glutamic acid added to HMB alone supplement to make 
isonitrogenous. 
2Patients with congestive heart failure, acute myocardial infarction, pneumonia or chronic obstructive pulmonary disease 
3Completed patients; 4Median (range); 5Median (interquartile range); 6Mean (SE) 
ADLs = activities of daily living; BF = breakfast; BIA = bioelectrical impedance analysis; BMI = body mass index; BUN = blood urea nitrogen; C = 





Human Immunodeficiency Virus; I = intervention; IU = international units; L = lunch;   MAMC = mid-arm muscle circumference; NR =  not reported; 
ONS = oral nutrition supplement; Pro = protein; RFcsa = rectus femoris cross sectional area; SGA = subjective global assessment; SF-36 = short-














Figure titles and legends 
Figure 1: Flow diagram of study selection process 
Figure 2: Risk of bias summary for all studies and outcomes 
Figure 3: Forest plot for the effect of HMB or supplements containing HMB on change 
in muscle mass 
Forest plot of a random effects meta-analysis of nine studies for change in muscle 
mass. Results are presented as standardized mean difference with 95% confidence 
intervals. Sub-group analysis are included for studies including HMB alone, HMB in 
combination with glutamine and arginine (HMB/ARG/GLN) and HMB incorporated in 
an oral nutrition supplement (HMB in ONS). 
Figure 4: Forest plot showing the effect of HMB or supplements containing HMB on 
change in body weight.  
Forest plot of a random effects meta-analysis of twelve studies for change in body 
weight. Results are presented as standardized mean difference with 95% confidence 
intervals. Sub-group analysis are included for studies including HMB alone, HMB in 
combination with glutamine and arginine (HMB/ARG/GLN) and HMB incorporated in 
an oral nutrition supplement (HMB in ONS). 
Figure 5: Forest plot showing the effect of HMB or supplements containing HMB on 
absolute strength. 
Forest plot of a random effects meta-analysis of six studies for absolute strength. 
Results are presented as standardized mean difference with 95% confidence intervals. 




with glutamine and arginine (HMB/ARG/GLN) and HMB incorporated in an oral 
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Blinding of outcome assessment
Blinding of participants and personnel
Allocation concealment
Random sequence generation
























Example search strategy 
Database: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) 
Daily and Ovid MEDLINE(R) <1946 to Present> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     HMB.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (2626) 
2     beta-hydroxy-beta-methylbutyrate.mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] (262) 
3     'beta hydroxy beta methylbutyrate'.mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] (262) 
4     1 or 2 or 3 (2674) 
5     muscle wasting.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 




6     muscle loss.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (1448) 
7     muscle mass.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (14504) 
8     skeletal muscle.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (107133) 
9     sarcopenia.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (5143) 
10     cache*.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (11284) 
11     physical fitness.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (31143) 
12     physical function.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 




13     fat free mass.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (6874) 
14     fat mass.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (18679) 
15     muscle strength.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (29829) 
16     grip strength.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (9374) 
17     strength.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (278916) 
18     body composition.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (53932) 
19     lean body mass.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 




20     maln*.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (47521) 
21     exp Muscle, Skeletal/ or exp Cachexia/ or exp Muscular Atrophy/ or exp Muscles/ 
(715992) 
22     exp Body Composition/ or exp Sarcopenia/ (53752) 
23     exp Muscle Strength/ or exp Body Weight/ (475694) 
24     exp Hand Strength/ or exp Muscle Strength Dynamometer/ (14388) 
25     exp Physical Fitness/ (27735) 
26     exp "Activities of Daily Living"/ (66805) 
27     5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 
21 or 22 or 23 or 24 or 25 or 26 (1576685) 
28     4 and 27 (311) 
29     exp animals/ not humans.sh. (4860425) 






Study or Subgroup 
Ekinci 2016 (42) 
Malafarina 2017 (44) 
Marcora 2005 (40) 
Olveira 2016 (37) 
Total (95% CI) 
Heterogeneity: Tau² = 0.00; Chi² = 1.22, df = 3 (P = 0.75); I² = 0% 
Test for overall effect: Z = 2.63 (P = 0.008) 
















IV, Random, 95% CI 
0.58 (0.07, 1.09) 
0.28 (-0.18, 0.74) 
0.43 (-0.23, 1.09) 
0.13 (-0.61, 0.87) 
0.38 (0.10, 0.66) 
Std. Mean Difference Std. Mean Difference 
IV, Random, 95% CI 
-1 -0.5 0 0.5 1 





Supplemental Figure 1: Forest plot of a random effects meta-analysis of four studies for 
handgrip strength. Results are presented as standardized mean difference with 95% 






Supplemental Figure 2: Forest plot of a random effects model of three studies for leg 






Study or Subgroup 
Fitschen 2017 (39) 
Marcora 2005 (40) 
Nishizaki 2015 (38) 
Total (95% CI) 
Heterogeneity: Tau² = 0.00; Chi² = 0.33, df = 2 (P = 0.85); I² = 0% 
Test for overall effect: Z = 2.73 (P = 0.006) 













IV, Random, 95% CI 
0.26 (0.05, 0.48) 
0.46 (-0.21, 1.12) 
0.20 (-0.63, 1.03) 
0.28 (0.08, 0.48) 
Std. Mean Difference Std. Mean Difference 
IV, Random, 95% CI 
-1 -0.5 0 0.5 1 





Supplemental Figure 3 – Funnel plot of change in muscle mass. 
Funnel plot describing the degree of publication bias. The standardized mean difference 
(SMD) of change in muscle mass is plotted on the x axis and the standard error (SE) of the 
SMD is plotted on the y axis. The vertical dotted line indicated the mean value of the 
standardized mean differences reported by the 9 included trials. Visual inspection of the 









Supplemental Figure 4 – Funnel plot of change in body weight. 
Funnel plot describing the degree of publication bias. The standardized mean difference 
(SMD) of change in body weight is plotted on the x axis and the standard error (SE) of the 
SMD is plotted on the y axis. The vertical dotted line indicated the mean value of the 










Supplemental Figure 5 – Funnel plot of change in absolute strength. 
Funnel plot describing the degree of publication bias. The standardized mean difference 
(SMD) of absolute strength is plotted on the x axis and the standard error (SE) of the SMD is 
plotted on the y axis. The vertical dotted line indicated the mean value of the standardized 
mean differences reported by the six included trials.  
 
